Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03537547 · ClinicalTrials.gov registry record · Phase 4
Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder
A Phase 4 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT03537547 is a Phase 4 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 6 participants.
The verdict
NCT03537547, a Phase 4 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study aims to determine whether the GeneSight Psychotropic test can result in better treatment outcomes for patients with treatment-naive major depressive disorder
Interventions
- OTHER GeneSight Psychotropic test
- DRUG FDA-approved antidepressant or antipsychotic treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-05-04 |
| Est. Completion | 2019-08-19 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03537547
The ClinicalTrials.gov registry entry for NCT03537547 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GeneSight Psychotropic test is the first listed.
NCT03537547 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03537547 about?
NCT03537547 is a clinical study titled "Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder". This study aims to determine whether the GeneSight Psychotropic test can result in better treatment outcomes for patients with treatment-naive major depressive disorder
What is the current status of trial NCT03537547?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2018-05-04. Estimated completion is 2019-08-19.
What interventions are being tested in trial NCT03537547?
The interventions under investigation include: GeneSight Psychotropic test (OTHER), FDA-approved antidepressant or antipsychotic treatment (DRUG).
Who is sponsoring clinical trial NCT03537547?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.